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Histone deacetylase (HDAC) inhibitors such as valproic acid (VPA) induce the expression of quiescent proviral
human immunodeficiency virus type 1 (HIV-1) and may deplete proviral infection in vivo. To uncover novel
molecular mechanisms that maintain HIV latency, we sought cellular mRNAs whose expression was diminished in
resting CD4 T cells of HIV-1-infected patients exposed to VPA. c-Myc was prominent among genes markedly
downregulated upon exposure to VPA. c-Myc expression repressed HIV-1 expression in chronically infected cell
lines. Chromatin immunoprecipitation (ChIP) assays revealed that c-Myc and HDAC1 are coordinately resident at
the HIV-1 long terminal repeat (LTR) promoter and absent from the promoter after VPA treatment in concert with
histone acetylation, RNA polymerase II recruitment, and LTR expression. Sequential ChIP assays demonstrated
that c-Myc, Sp1, and HDAC1 coexist in the same DNA-protein complex at the HIV promoter. Short hairpin RNA
inhibition of c-Myc reduces both c-Myc and HDAC1 occupancy, blocks c-Myc repression of Tat activation, and
increases LTR expression. These results expand the understanding of mechanisms that recruit HDAC and maintain
the latency of HIV-1, suggesting novel therapeutic approaches against latent proviral HIV infection.
The molecular mechanisms that establish or maintain hu-
man immunodeficiency virus type 1 (HIV-1) latency are in-
completely understood. Several mechanisms, which are not
mutually exclusive, have been proposed to drive HIV-1 provi-
ral quiescence or latency (14, 21, 37). As the HIV-1 provirus is
often integrated into active regions of the host genome, the
chromatin environment and the interaction of cellular and
viral transcriptional regulators are likely to be critical for in-
ducing and maintaining HIV-1 latency (5, 27, 37, 44). A sur-
prisingly robust induction of HIV-1 transcription in response
to deacetylase inhibitors has been observed (19, 22, 49).
Histone modifications remodel the chromatin of the viral
promoter region but also regulate the functional properties of
cellular and viral transcription factor binding to the HIV-1
long terminal repeat (LTR) (28, 40, 45, 50). By altering his-
tones, recruiting other chromatin-remodeling factors, and al-
tering the activity of transcription factors, histone deacetylases
(HDACs) appear to be critical for the repression of HIV-1
transcription and the maintenance of HIV-1 latency (45, 50).
In support of the clinical relevance of this model, we found that
the administration of an HDAC inhibitor, valproic acid (VPA),
in the context of intensified highly active antiretroviral therapy
depleted latent HIV-1 infection in vivo (23), although this was
not observed in a clinical cohort on standard antiretroviral
therapy and incidentally coadministered VPA (41). Additional
clinical studies to test this approach are ongoing.
Alternative therapeutic approaches to proviral HIV infec-
tion may be needed. As HDAC inhibition can modify the
expression of a subset of human genes (45) and VPA modifies
the activity of other host enzymes (26), we studied changes in
host gene expression induced by VPA with resting CD4 T
cells of HIV-infected patients. We reasoned that perturbations
in gene expression pathways might lead to the identification of
novel mechanisms that maintained HIV proviral quiescence.
We found that c-Myc expression was markedly downregulated
when resting CD4 lymphocytes from HIV-infected patients
were exposed to VPA, suggesting that c-Myc may lead to the
repression of HIV expression by a novel mechanism.
Myc is a member of the basic helix-loop-helix leucine zipper
(bHLH-Zip) transcription factor family required for growth,
proliferation, and differentiation. One member of the Myc
family, the proto-oncogene c-Myc, is implicated in a variety of
physiological processes, including the transcriptional regula-
tion of many genes (6, 11, 12). When dimerized with the
bHLH-Zip protein Max, c-Myc binds to the E-box sequence
CACGTG and activates the transcription of target genes; how-
ever, Myc has also been shown to repress the transcription of
several genes such as the C/EBP, H-ferrin, IRP2, LFA-1
receptor, gadd45, platelet-derived growth factor, and p15Ink4b
genes (1, 17, 18, 42, 47). One current model suggests that Myc
represses transcription through functional interference with
transcriptional activators (11). Alternatively, c-Myc may also
block transcription by recruiting HDAC1 (39). c-Myc was re-
cently shown to recruit the corepressor Dnmt3a to the p21Cip1
gene promoter and in association with DNA methyltransferase
activity in vivo (3). Ectopic expression of c-Myc has been
shown to decrease HIV-1 expression, but the molecular mech-
anism for this observation has not been determined (43).
To our surprise, we found that c-Myc is recruited to the HIV
LTR by Sp1 and that c-Myc in turn recruits HDAC1 and blunts
HIV promoter expression. This is the third mechanism re-
ported to recruit HDAC1 to the HIV LTR and induce chro-
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matin remodeling. This finding highlights a unique redundant
use of this cellular enzyme by the HIV LTR to maintain qui-
escence in resting T cells and strongly suggests that mecha-
nisms that recruit HDAC1 and maintain its activity at the LTR
are important targets for antilatency therapies.
MATERIALS AND METHODS
Cell culture and VPA treatment. HeLa-CAT-CD4 and J89 cells were main-
tained in Dulbecco’s modified Eagle medium and RPMI 1640 medium, respec-
tively, with 10% fetal bovine serum containing 100 g/ml streptomycin and 100
units/ml of penicillin. HeLa-CAT-CD4 and primary resting CD4 T cells (2 
106 cells) were split into 100-mm culture dishes and grown overnight, VPA was
added, and, after incubation for the appropriate time, the cells were collected.
Proteins were extracted with Cellytic MT (Sigma, St. Louis, MO) for Western
blotting or immunoprecipitation (IP), or the cells were cross-linked for chroma-
tin IP (ChIP) assays.
Microarrays and analysis. Microarrays were obtained from Agilent Technol-
ogies (Palo Alto, CA) and consisted of 23,500 60-mer oligonucleotides designed
for broad coverage of the human genome. Lymphocytes were obtained by con-
tinuous-flow leukophoresis from stable, HIV-infected volunteers on antiretrovi-
ral therapy with plasma HIV-1 RNA levels of 50 copies/ml for more than 6
months and CD4 cell counts of 300 cells/ml. Committee-approved informed
consent was obtained from all patients. The isolation of CD4 T cells was per-
formed as described in detail previously (23, 37, 49). Total RNA from untreated,
VPA-treated, or phytohemagglutinin (PHA)-treated resting CD4 T cells ob-
tained from HIV-infected, aviremic subjects was reverse transcribed, subjected
to in vitro transcription, labeled with Cy3 and Cy5, and hybridized as described
previously (15). For each treatment, RNA samples were processed and hybrid-
ized against a reference pool derived from RNA of the untreated cells from the
same subject. Scanned intensities were normalized and converted to log ratio
values, and significant (P  0.01 with greater than a 1.5 to 2 difference)
changes in gene expression were identified using the Rosetta Resolver system
(Rosetta Biosoftware, Seattle, WA).
Transfection. Cells (3  105) were seeded in 12-well plates and grown over-
night. The expression plasmids pCMV-empty vector, pCMV-Tat, pCGN-c-Myc
(a gift of W. Tansey, Cold Spring Harbor Laboratory) (38), pILIC-CAT, pNFA-
CAT, and pSpC-CAT (34) were purified and cotransfected by using Lipo-
fectamine 2000 (Invitrogen, Carlsbad, CA) and then incubated for 48 to 96 h.
RNA preparation and real-time PCR. Total RNA was isolated using TRIzol
(Invitrogen), and the RNA was treated with DNase (RNase A-free; Invitrogen).
Chloramphenicol acetyltransferase (CAT) expression was then assayed by SYBR-
based real-time PCR (One-Step Real-Time RT-PCR kit; Applied Biosystems) with
0.1 g total RNA and 50 nM specific primers for 40 cycles. The CAT primers were
CAT-5F (5-TTC GTC TCA GCC AAT CCC TGG GTG A-3) and CAT-6R
(5-CCC ATC GTG AAA ACG GGG GCG AA-3). The GAPDH (glyceralde-
hyde-3-phosphate dehydrogenase) primers were GAPDH-3F (5-CAC CAT GGA
GAA GGC TGG GGC TCA-3) and GAPDH-3R (5-TGA CGA ACA TGG
GGG CAT CAG CAG A-3). The green fluorescent protein (GFP) primers were
GFP-5Jor (5-GGA GCG CAC CAT CTT CTT CA-3) and GFP-3Jor (5-AGG
GTG TCG CCC TCG AA-3). Monitoring mRNA expression of GFP is a more
direct measure of transcription that is less likely to measure the secondary effects of
c-Myc knockdown. The relative quantification was analyzed with Applied Biosys-
tems relative quantification software.
ChIP and sequential ChIP assays. The following antibodies were used: anti-
acetyl-histone H4, anti-HP1, anti-RNA polymerase CTD, anti-AceH4 (Upstate
Biotechnology), anti-DNMT3a (IMGENEX, San Diego, CA), anti-HDAC1
(Abcam, Cambridge, MA), and anti-c-Myc (Santa Cruz Biotech, Santa Cruz, CA).
ChIP assays were performed as previously described (14). PCR was carried out with
the following primers: LTR7F (5-TGG AGG TTT GAC AGC CGC CTA-3) and
LTR8R (5-AGG CTT AAG CAG TGG GTT CCC TA-3). The following primers
were used for the LTR downstream PCR. For HeLa-CAT-CD4 cells, the primers
were DS1 (5-TTC GTC TCA GCC AAT CCC TGG GTG A-3) and DS2 (5-CCC
ATC GTG AAA ACG GGG GCG AA-3). For J89 cells, the downstream primers
used were reported previously (45).
A quantitative real-time PCR assay was performed to analyze the enrichment
of the proteins specific to the HIV-1 LTR region. The following primers were
used for quantitation: LTR-7F (5-AGC CCT CAG ATC CTG CAT ATA AGC
A-3) and LTR-8R (5-TAG CCA GAG AGC TCC CAG GCT CAG A-3). The
relative changes in ChIP products are quantitated by real-time PCR of a fraction
of the input and of immunoprecipitated promoter fragments. A CT value was
calculated for each sample by subtracting the threshold cycle (CT) value for the
input from the CT value obtained for the ChIP sample. A CT value was then
calculated by subtracting the CT value for the immunoprecipitated sample from
the CT value for the corresponding control IP with isotype immunoglobulin G
(IgG). Differences (n-fold) (ChIP relative to control IgG ChIP or untreated
ChIP relative to treated ChIP) were then determined by raising 2 to the CT
power.
For sequential ChIP assays, the initial ChIP was performed with the indicated
antibodies, chromatin was eluted with dithiothreitol, and a second ChIP was then
carried out. Amplified products were quantitated by real-time PCR. The relative
binding of the indicated proteins to the HIV-1 LTR region was calculated from
real-time PCR data as described above.
RNA interference. Human Sp1 small interfering RNA expression plasmid
pKD-Sp1-v1 and its mismatch vector pKD-NegCon-v1 were purchased from
Upstate, while human c-Myc small interfering RNA expression plasmid
pSUPER-c-Myc and its mismatch control vector pSUPER-GL2 were gifts from
Ernest Martinez (10). HeLa-CAT-CD4 or J89 cells (3  105) were seed into
six-well plates, and after incubation overnight, 2.5 g of the plasmids was trans-
fected into the cells with Lipofectamine 2000 or TransIT-Jurkat reagent (Mirus,
Madison, WI). At 4 days, the cells were collected, and proteins were extracted
with Cellytic MT (Sigma) for Western blotting, or the cells were cross-linked for
ChIP assays.
RESULTS
Expression of c-Myc is reduced in resting CD4 T cells of
aviremic HIV-infected patients following exposure to VPA. To
discover additional pathways that maintain latency, we sought
genes whose expression in primary cells was decreased by
VPA. Under institutional review board-approved informed
consent, resting CD4 T cells were collected from three HIV-
1-infected patients and on two occasions from a fourth patient.
In all patients, viremia was stably suppressed by antiretroviral
therapy. We exposed patients’ cells for 6 h to 2 g/ml PHA and
20 U/ml interleukin-2 (IL-2) or 1 mM VPA and IL-2, condi-
tions in which HIV is routinely recovered from patients’ resting
CD4 T cells in outgrowth assays (49, 50). As a negative
control, cells were exposed to IL-2 (20 U/ml) alone, a condition
in which the recovery of HIV is not observed. Total RNA was
obtained and profiled by microarray.
We found that in primary resting CD4 T cells from these
HIV-infected patients, c-Myc gene expression was significantly
downregulated by VPA. Overall, only 42 genes were consistently
downregulated (P  0.01) by an average of more than threefold,
and 157 genes were consistently upregulated (P  0.01) by an
average of more than threefold. c-Myc was strikingly downregu-
lated (Fig. 1A): only 24 of the 23,757 reporters studied were
downregulated to a quantitatively greater extent.
In contrast, the expression of the other transcription factors
of known relevance to HIV promoter activation (e.g., Rel/NF-
	B, Sp1, Fos, Jun, and NFAT) (7, 13, 27) was unchanged (Fig.
1B). As expected, mitogen activation induced the expression of
a panoply of genes associated with HIV LTR activation, such
as Sp1 and NF-	B (Fig. 1B). PHA also upregulated c-Myc
expression (Fig. 1A), but presumably, this effect is over-
whelmed by the multiple activation pathways induced by mi-
togen.
The downregulation of c-Myc expression after treatment
with HDAC inhibitors has been reported for cancer cells (2,
20, 25) and HIV-infected cell lines (45). Furthermore, de la
Fuente et al. (7) previously reported that mRNA expression of
c-Myc was upregulated in latently HIV-1-infected ACH2 cells
compared with uninfected CEM cells. The overexpression of
c-Myc has been shown to decrease the expression of an HIV
LTR reporter plasmid in Jurkat T cells (43). These findings
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suggest the possibility that c-Myc may downregulate HIV-1
transcription and promote HIV-1 latency. To confirm the
changes observed in microarray analyses, protein expression of
c-Myc was measured in HeLa-CAT-CD4 cells and in resting
CD4 T cells isolated from aviremic, HIV-infected volunteers
after treatment with VPA. The protein level of c-Myc was
reduced by VPA, in concert with decreased c-Myc mRNA
expression. Due to an effect at the posttranscriptional level,
HDAC1 protein expression was also diminished in the cell line
and patient cells (Fig. 1C), although HDAC1 mRNA expres-
sion was not directly downregulated (Fig. 1B).
VPA alters chromatin structure by depleting several mem-
bers of the structural maintenance of chromatin protein family,
proteins associated with the structural maintenance of chro-
matin, DNA methyltransferases, and heterochromatin proteins
(8, 30, 33, 48). The DNA methyltransferase Dnmt3a was re-
cently found to be required for c-Myc inhibition of the p21
promoter (3). However, as shown in Fig. 1C, there was no
significant change in the expression of the Dnmt3a protein in
HeLa-CAT-CD4 cells.
c-Myc negatively regulates HIV-1 transcription. To examine
the role of c-Myc in HIV-1 LTR-directed transcriptional reg-
FIG. 1. Expression of c-Myc in latently HIV-1-infected patient cells and HeLa-CAT-CD4 cells after VPA treatment. (A) c-Myc expression is
significantly decreased upon exposure to VPA (P value for a change of 1.5-fold is 0.01). (B) In the resting CD4 T cells of four HIV-infected
patients, c-Myc RNA expression levels uniformly and substantially decreased following VPA exposure (red box). c-Myc RNA expression was
unaffected by 20 U/ml IL-2 and upregulated modestly in some patients’ cells following mitogen activation. (C) Decreased c-Myc protein expression
48 h after treatment with VPA. HeLa-CAT-CD4 cells or resting CD4 T cells isolated from HIV-infected, highly active antiretroviral therapy-
treated donors were treated with the amount of VPA indicated. The Western blot shows protein expression of c-Myc, HDAC1, the histone
demethylase Dnmt3a, and GAPDH.
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ulation, c-Myc was transiently coexpressed with HIV Tat in
HeLa-CAT-CD4 cells, and 48 h after transfection, absolute
CAT RNA expression was assayed using real-time PCR. c-Myc
itself had no significant effect on the low level of basal HIV-1
LTR expression but induced significant and reproducible inhi-
bition of Tat-activated HIV-1 LTR expression (Fig. 2A). Tat-
activated expression of LTR-driven CAT mRNA was de-
creased by c-Myc in a dose-dependent fashion (Fig. 2B), while
the transient expression of Tat itself was not affected by c-Myc.
Both c-Myc and HDAC1 are tethered to the HIV-1 LTR
promoter region. Through the recruitment of corepressors,
DNMT3a or HDACs, c-Myc can inhibit the expression of its
target p21, cad, or NDRG2 gene (3, 34). To strengthen the
hypothesis that c-Myc plays a direct molecular role in the
repression of HIV LTR expression, ChIP assays were done to
seek evidence of c-Myc occupancy at the HIV-1 promoter.
HeLa-CAT-CD4 cells were treated with 4 mM VPA or vehicle
for 4 h, at which time cells were cross-linked and sonicated,
DNA-protein complexes were collected by centrifugation, and
ChIP was performed. c-Myc was present at the nucleosome 1
(Nuc-1) region of the HIV LTR in the basal state, and occu-
pancy was decreased in cells exposed to the HDAC inhibitor
VPA (Fig. 3A). As previously demonstrated (14), HDAC1 was
also present at Nuc-1 in the basal state, and occupancy dimin-
ished after VPA exposure. In concert with reduced c-Myc and
HDAC1 occupancy, the binding of acetylated histone H4 in-
creased (Fig. 3A). Although the methyltransferase Dnmt3a
interacts with c-Myc at other promoters, it was not detected at
the HIV LTR and therefore served as a negative control. RNA
polymerase II occupancy at the Nuc-1 region and a down-
stream site (45) also increased after VPA exposure. Notably,
the specificity of c-Myc and HDAC1 ChIP was illustrated by
the lack of occupancy at the downstream site.
Extending these findings in the context of a lymphocytic cell
line, we observed similar binding of c-Myc and HDAC1 to the
HIV-1 LTR region in latently HIV-1-infected J89 Jurkat T
cells (Fig. 3B). As in the HeLa-CAT-CD4 cell line, c-Myc and
HDAC1 recruitment was disrupted after VPA exposure.
Again, no significant binding of Dmnt3a to the HIV-1 LTR
was observed, and c-Myc and HDAC1 were not detected
downstream of the Nuc-1 region. These results, together with
the findings described above, suggest that c-Myc is a negative
regulator of HIV-1 gene transcription via the recruitment of
HDAC1 to the HIV-1 LTR promoter region.
c-Myc is associated with HDAC1. HDAC inhibitors displace
HDAC1 from the HIV-1 LTR Nuc-1 region and increase the
acetylation of histone H4 at Nuc-1 (14). Both c-Myc mRNA
and protein levels diminished when the cells were treated with
VPA (Fig. 1). Therefore, c-Myc may recruit HDAC1 to the
LTR, and HDAC inhibitors may act both by blocking HDAC
enzyme action, thus inhibiting factor interactions upregulated
by acetylation, and by decreasing the cellular levels of key
repressor factors, including c-Myc. c-Myc may act by direct
interactions with HDAC1 or may exist in a complex that in-
cludes HDAC1.
We validated the previously reported ability of c-Myc and
HDAC1 to directly interact (3, 34), as in HeLa-CAT-CD4 and
J89 cells. We found c-Myc present in complexes immunopre-
cipitated by anti-HDAC1, and conversely, HDAC1 was
present in complexes immunoprecipitated by anti-c-Myc (not
shown).
To demonstrate that c-Myc and HDAC1 coexist within the
same protein complex resident in the Nuc-1 region of the HIV
LTR, sequential ChIP assays were performed. In such assays,
an initial ChIP was performed with an antibody that recognizes
one protein. The precipitated chromatin-DNA complex was
washed and eluted, and a second IP was performed with the
same antibody, a second antibody, or control isotype IgG.
When ChIP was first performed with anti-c-Myc (Fig. 4),
sequential ChIP showed the occupancy of HDAC1 in the same
protein-DNA complex. As the cross-linking distance of form-
FIG. 2. Overexpression of c-Myc negatively regulates HIV-1 LTR
transcription. (A) c-Myc blunts Tat-activated LTR expression in
HeLa-CAT-CD4 cells. pCMV vector, pCMV-Tat, pGCN-c-Myc, or
pGCN-c-Myc plus pCMV-Tat were transfected into HeLa-CAT-CD4
cells. CAT reporter gene expression was assayed by real-time PCR
after 48 h. RNA PCR demonstrates that GAPDH (loading control)
and transfected Tat expression levels are equivalently unaffected by
c-Myc. Relative CAT reporter gene expression was normalized to a
value of 1.0 for pCMV-transfected cells. Bars indicate standard errors
of the means for three independent experiments. P values are given for
comparisons with vector control. n.s., not significant. (B) Dose-depen-
dent inhibition of Tat activation by c-Myc. LTR expression was mon-
itored in the presence of increased ratios of pGCN-c-Myc to pCMV-
Tat (1:1, 1:2, 1:3, and 1:4). At the highest dose of c-Myc vector, Tat
activation was repressed 5.7-fold (P  0.001).
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aldehyde is 4 Å, these results do not prove a direct interaction
of these proteins but provide evidence of close occupancy at
the LTR initiation region. The specificity of these results is
illustrated by the lack of significant IP using Dnmt3a, a cellular
factor that can interact with c-Myc but for which there is no
evidence of occupancy at the Nuc-1 region of the LTR. The
finding that the IP product is decreased when a different an-
tibody is used during the second ChIP (e.g., less product for
ChIP with c-Myc/c-Myc than with c-Myc/HDAC1) may illus-
trate that not all c-Myc-containing complexes include HDAC1
or might simply be an artifact of differing antibody affinities for
epitopes that are accessible within the DNA-protein complex
under study. Specificity was again demonstrated, as these com-
plexes were not detected downstream of Nuc-1.
Binding of c-Myc to the HIV-1 LTR promoter is mediated by
Sp1. ChIP assays demonstrated that c-Myc bound the HIV-1
LTR, but the mechanism of its recruitment was unclear. Given
that LSF/YY1 and NF-	B p50 can recruit HDAC1 (46, 50), a
link for c-Myc to HDAC1 recruitment was unproven. Although
a putative E box in the initiator region (Inr) has been proposed
to be a site for c-Myc binding, there is no evidence that c-Myc
binding occurs at that site (18). Furthermore, while we have
demonstrated an association between c-Myc and the HIV-1
LTR promoter, c-Myc can be recruited to promoters by other
transcription factors or corepressors without direct promoter
binding (32).
Given the host transcription factors known to play central
roles at the LTR Nuc-1 region, a prime candidate among the
network of c-Myc binding partners with potential to recruit
c-Myc to the HIV LTR was Sp1. Sp1 has been shown to
directly interact with c-Myc (12). To determine if Sp1 recruits
c-Myc to the HIV-1, LTR reporter assays were performed (24).
Wild-type HIV-1 LTR CAT plasmids (pILIC-CAT) or an
LTR reporter lacking Sp1 binding sites (pSpA-CAT) was co-
transfected into HeLa cells with and without Tat and c-Myc
expression vectors (Fig. 5A). While the activation potential of
the HIV LTR is diminished when Sp1 sites are mutated, such
constructs can be activated or respond to Tat, and viral clones
encoding Sp1 mutations can replicate (24, 31, 35).
c-Myc expression inhibited wild-type HIV-1 LTR expres-
sion, as measured by real-time PCR quantitation of LTR-
FIG. 3. Recruitment of c-Myc to the HIV-1 LTR region. (A) Binding of c-Myc, HDAC1, acetylated H4, and RNA polymerase II to the Nuc-1
region of the HIV-1 LTR in HeLa-CAT-CD4 cells. VPA exposure resulted in significantly decreased occupancy of HDAC1 and c-Myc, increased
occupancy of RNA polymerase II and acetylated histone H4 at the Nuc-1 region, and an increase in only RNA polymerase II detection downstream
(DS) of the initiation region. Amplified products were quantitated by real-time PCR. The relative binding of indicated proteins to the HIV-1 LTR
region was measured after normalization with that of input DNA and IgG. (B) Binding of c-Myc and HDAC1 to HIV-1 LTR in latently
HIV-1-infected J89 lymphocytic cells. VPA exposure again resulted in significantly decreased occupancy of HDAC1, c-Myc, acetylated histone H4,
and RNA polymerase II near Nuc-1 and little change at the downstream site. Amplified products were quantitated by real-time PCR. The relative
binding of indicated proteins to the HIV-1 LTR region was measured after normalization with that of input DNA and IgG. Assays were performed
in triplicate (or more), and the significance of changes was tested by a two-sided t test. P values are 0.05 for all changes of at least twofold and
0.01 for all changes of at least threefold.
FIG. 4. c-Myc and HDAC1 are found in the same complex at the
HIV LTR initiator region. Sequential ChIP assays were performed
after an initial IP with anti-c-Myc. Protein-DNA complexes were de-
tected near the Nuc-1 region after a second IP with anti-c-Myc or
anti-HDAC1 but not in the downstream (DS) region and not with
isotype IgG or antibody (Ab) against the methyltransferase Dnmt3a.
Real-time PCR quantitation of DNA IP, as detailed in Materials and
Methods, is indicated.
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driven CAT mRNA, but had no significant effect on the Tat-
driven expression of the mutant HIV-1 LTR reporter lacking
Sp1 binding sites. In cells transfected with a mutant HIV-1
LTR reporter lacking NF-	B binding sites (pNFA-CAT), c-
Myc was still able to repress HIV-1 expression, although as
previously demonstrated (31), the activation of HIV-1 with Tat
was relatively lower than that of wild-type and Sp1-deleted
mutant HIV-1 LTR. This suggests that Sp1 recruits c-Myc to
the HIV-1 LTR with subsequent recruitment of HDAC1 and
LTR repression.
To demonstrate that c-Myc and Sp1 coexist within the same
protein complex resident in the Nuc-1 region of the HIV LTR,
sequential ChIP assays were again performed. When ChIP was
first performed with anti-Sp1 (Fig. 5B), sequential ChIP
showed the occupancy of c-Myc and HDAC1 in the same
protein-DNA complex. Again, these results do not prove a
direct interaction of these proteins but provide evidence of
close co-occupancy at the LTR initiation region. The specificity
of these results was illustrated by the lack of significant IP
using Dnmt3a or at the downstream site.
shRNA inhibition of Sp1 expression reduces c-Myc and
HDAC1 occupancy and repression of LTR expression. To di-
rectly demonstrate the role of Sp1 in c-Myc recruitment to the
HIV-1 LTR region in vivo, we used a short hairpin RNA
(shRNA) that specifically depleted Sp1 protein expression and
tested if the knockdown of Sp1 would disrupt c-Myc binding to
the HIV-1 promoter. Transfection of pKD-Sp1-v1 specifically
depleted Sp1 in HeLa-CAT-CD4 cells, whereas transfection of
a vector encoding a scrambled sequence did not (Fig. 6A).
However, although c-Myc expression was unchanged (Fig. 6A)
after Sp1 knockdown, when measured by ChIP in the same
extract, the occupancy of Sp1, c-Myc, and HDAC1 at the LTR
was significantly decreased (Fig. 6B).
To measure the effect of Sp1 knockdown on the c-Myc
inhibition of HIV-1 activation, a cotransfection of c-Myc and
Tat expression vectors was performed along with the active and
FIG. 5. Sp1 mediates c-Myc regulation of HIV-1 LTR expression. Sp1 sites are required for c-Myc-mediated repression, and Sp1 and c-Myc
coexist within a complex at the LTR. (A) Expression plasmids pCMV-empty vector, pCMV-Tat, and pcDNA-c-Myc and the wild-type (wt)
pILIC-CAT, pSpA-CAT, and pNFA-CAT reporter plasmids were cotransfected into HeLa cells using Lipofectamine 2000 reagent. CAT
expression was analyzed by real-time RT-PCR. Tat-activated LTR RNA expression is displayed, with normalization to the cells transfected with
pCMV-Tat for each of the reporter assays. PCR products for the GAPDH loading control and transfected Tat are shown. Error bars indicate
standard errors of the means for three independent experiments. (B) Sequential ChIP assays were performed after an initial IP with anti-Sp1. A
protein-DNA complex near Nuc-1 was recovered after a second IP with anti-Sp1, anti-c-Myc, or anti-HDAC1 (P  0.01) but not at the downstream
region or with isotype IgG or antibody (Ab) against the methyltransferase Dnmt3a. Real-time PCR quantitation of DNA IP, as detailed in
Materials and Methods, is indicated.
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control Sp1 shRNA vectors described above. Control Sp1
shRNA did not affect Tat activation or c-Myc inhibition of Tat
activation. As expected, Tat activation was blunted by Sp1
shRNA, although RNA expression was still activated 20-fold
above baseline by Tat. However, after Sp1 knockdown, c-Myc
did not inhibit Tat activation (Fig. 6C). Tat expression was
unchanged by RNA interference targeted at Sp1. These find-
ings demonstrate that Sp1 is critical for both c-Myc binding to
the HIV-1 LTR and the repression of Tat-dependent HIV-1
activation by HDAC1 recruitment mediated by c-Myc.
We then used an shRNA that specifically depleted c-Myc
protein expression and tested if the knockdown of c-Myc would
diminish HDAC1 recruitment to the HIV-1 promoter. Trans-
fection of pSUPER-Myc827 specifically depleted c-Myc (10),
whereas transfection of a vector encoding a scrambled se-
quence did not (Fig. 6D). c-Myc knockdown resulted in a
significant decrease in the occupancy of c-Myc and HDAC1 at
the LTR (Fig. 6E).
Consistent with these findings, the knockdown of c-Myc in
the J89 Jurkat cell line (Fig. 6F), encoding an intact provirus
expressing Tat, results in the upregulation of LTR-driven GFP
expression (Fig. 6G). The extent of LTR induction is similar to
that previously seen when HDAC1 recruitment by LSF/YY1
was inhibited (5).
DISCUSSION
While many factors may be involved in HIV-1 latency, the
chromatin environment plays an important role in maintaining
proviral quiescence (29). As HIV-1 integrates most frequently
into genes that are transcribed in resting CD4 T cells (13),
chromatin at the proviral promoter may play an important role in
maintaining quiescence in the minority of proviral genomes that
enter latency. Although we initially sought new mechanisms that
drive proviral quiescence, here, we discovered a novel additional
mechanism that may contribute to the maintenance of proviral
latency. In VPA-treated cells from latently HIV-1-infected pa-
tients, we found that the mRNA expression of c-Myc was signif-
icantly downregulated. Reduced protein expression was con-
firmed in primary resting CD4 cells obtained from HIV-infected
patients treated with VPA. Gene reporter analysis further con-
firmed c-Myc repression of HIV-1 expression.
c-Myc is associated with HDAC1 in HeLa-CAT-CD4 cells,
and in concert with LTR upregulation induced by the HDAC
inhibitor VPA, c-Myc binding to the HIV-1 promoter was
disrupted. Both decreased binding of c-Myc to the HIV-1 pro-
moter and decreased protein levels of c-Myc following VPA
treatment may contribute to the downregulation of c-Myc oc-
cupancy at the HIV LTR. However, reduced protein levels of
c-Myc were seen only after 48 h of VPA exposure, whereas
occupancy was significantly decreased within 4 h. c-Myc occu-
pancy might be diminished by increased histone acetyltrans-
ferase activity after VPA exposure or other direct or secondary
consequences of histone deacetylase inhibition.
Several models are suggested for c-Myc repression of target
genes. Among them, c-Myc appears to be recruited to the
HIV-1 promoter by its interaction with Sp1. The core pro-
moter region of the HIV-1 LTR contains three tandem Sp1
binding sites and two NF-	B elements located upstream of the
TATA box of HIV-1. The insensitivity of the Sp-1 binding site
mutant HIV-1 LTR to suppression by ectopically expressed
c-Myc indicated that Sp-1 might mediate c-Myc binding to the
HIV-1 LTR. This was supported by the specific shRNA-medi-
ated inhibition of Sp-1 expression.
As YY1 can interact with c-Myc (43), it is possible that these
factors interact in a supercomplex to recruit HDAC to the LTR.
However, while this might be so, each factor appears to be lim-
iting for HDAC recruitment, as the knockdown of c-Myc or p50
or small-molecule inhibition of LSF binding (and thereby YY1
recruitment) is capable of disrupting the binding of HDAC1 to
the HIV-1 LTR and activating HIV-1 expression (5, 46).
Of course, the complexities of HIV LTR regulation require
further study. For example, while c-Myc downregulation ac-
companies VPA-mediated LTR depression, c-Myc upregula-
tion accompanies mitogen-mediated LTR activation. This par-
adox is not fully understood but is likely related to the
markedly different global gene expression patterns induced by
VPA and mitogen activation (Fig. 1B).
Similarly, c-Myc downregulation is suggested to be partially
required for the lung Krüppel-like factor (LKLF)-mediated
programming of quiescence in T-cell function, at least in a
Jurkat cell line system. Again, however, several other gene
pathways in addition to c-Myc mediate the effects of LKLF on
Jurkat cells (4).
When HDAC inhibitors are administered to latently HIV-1-
infected cells, transcriptional repression mediated by HDACs
along with other corepressors is abrogated, leading to the ex-
pression HIV from an integrated genome (5, 14, 36, 45). Sev-
eral mechanisms (Fig. 7) have been reported to recruit
HDAC1 to the HIV LTR (5, 14, 16, 46). The relative impor-
tance of each of these mechanisms in vivo is unclear so far,
although a specific molecular inhibition of HDAC recruitment
via either LSF/YY1 was sufficient to disrupt latent HIV infec-
tion in the resting CD4 T cells of HIV-infected patients (19).
FIG. 6. c-Myc occupancy at the HIV-1 LTR and its repression of Tat activation require Sp1. (A) Specific shRNA-mediated knockdown of Sp1
protein expression. HeLa-CAT-CD4 cells were transfected with pKD-sp-v1 plasmids directed against Sp1 or pKD-Neg-con-v1 (control) plasmids.
Sp1, c-Myc, and GAPDH protein levels were assessed by immunoblotting. (B) Reduced occupancy of Sp1, c-Myc, and HDAC1 at the LTR initiator
region upon Sp1 depletion. ChIP assays were performed after Sp1 knockdown, and changes in binding were quantitated by real-time PCR.
(C) Blockade of c-Myc inhibition of Tat-mediated HIV-1 transcription following Sp1 knockdown. As expected, Tat activation is less efficient after
Sp1 knockdown, but a 20-fold increase of RNA expression over the basal level was still measured. However, c-Myc expression had no effect of Tat
activation after Sp1 knockdown. PCR products for the GAPDH loading control and transfected Tat are shown. Error bars indicate standard errors
of the means for three independent experiments. n.s, not significant. (D) Specific shRNA-mediated knockdown of c-Myc protein expression.
(E) Similarly, occupancy of c-Myc and HDAC1 is reduced at the LTR initiator region upon c-Myc depletion. (F) shRNA in the J89 Jurkat T-cell
line directed against c-Myc depletes c-Myc protein levels and results in the significant upregulation of HIV-1 LTR expression. (G) Knockdown of
c-Myc in J89 cells results in the significant upregulation of HIV LTR expression.
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The apparent evolution within the HIV promoter of mul-
tiple mechanisms through which HDAC1 is recruited is
striking and of high potential therapeutic significance.
HDAC1 is recruited to the highly conserved initiator region
of the HIV promoter by three distinct transcription factor
complexes. These complexes are comprised of canonical
factors that are ubiquitous in cell types infected by HIV-1
and required for both basal and activated promoter expres-
sion. It would seem less likely, therefore, that a subpopula-
tion of latently infected cells would be unresponsive to this
redundant mechanism of regulation or that the HIV LTR
could function in the absence of these core factors that are
capable of recruiting HDAC1. This suggests that potent
inhibitors specific for HDAC1 in the HIV LTR might be
broadly effective therapeutics to disrupt latent HIV infec-
tion and might avoid toxicities that could accompany the
global inhibition of other members of the HDAC family.
Therapeutics that do not directly inhibit HDAC but that
prevent its occupancy or action at the HIV LTR may be
considered as an alternate or an additional approach. For
example, small-molecule reagents that inhibit c-Myc have
entered early clinical testing in oncology (9).
Ultimately, just as the replicative stage of the HIV life cycle
is attacked at multiple steps, the DNA stage of the HIV life
cycle might be attacked by the administration of antilatency
therapeutics in combination or in series to disrupt the main-
tenance of latency and induce the death of productively in-
fected cells.
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